Skip to content

Study · In vitro (cell-free) · 2020

1 result

Nontuberculous Mycobacteria Show Differential Infectivity and Use Phospholipids to Antagonize LL-37.

Honda JR, Hess T, Carlson R, Kandasamy P, Nieto Ramirez LM, Norton GJ, Virdi R, Islam MN, Mehaffy C, Hasan NA, Epperson LE, Hesser D and 6 more

Show all authors

Alper S, Strong M, Flores SC, Voelker DR, Dobos KM, Chan ED

American journal of respiratory cell and molecular biology1 Mar 2020Cited by 16 (Europe PMC)

PMID31545652 (opens in a new tab)PMCIDPMC7055699 (opens in a new tab)DOI10.1165/rcmb.2018-0278oc (opens in a new tab)PepBankPUB-31545652
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cell-free)Mechanism

    In biochemical assays, modified phospholipids from nontuberculous mycobacteria were implicated as candidate antagonists of LL‑37 antibacterial activity.

    In plain wordsIn lab tests, certain fat molecules from nontuberculous mycobacteria may block the germ-killing action of LL‑37.

    Peptide
    LL-37
    Outcome
    Not applicableAntagonism of LL-37 antibacterial activity by NTM phospholipids
    Study

    n: not reported in source

    Biochemical assays with nontuberculous mycobacteria
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Our biochemical assays implicate modified phospholipids, which may include a phosphatidylinositol or cardiolipin backbone, as candidate antagonists of LL-37 antibacterial activity.
    1 context sentence
    Summary · context
    We also assessed their capacity to evade killing by the antibacterial peptide cathelicidin (LL-37).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:57 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.